Loading...
Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer
Durvalumab after concurrent chemoradiation has significantly improved survival in stage III non-small cell lung cancer (NSCLC). However, there is limited data evaluating the utilization and challenges to deliver durvalumab consolidation in the real world. We assessed the use of consolidative durvalu...
Na minha lista:
| Udgivet i: | Radiother Oncol |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7523024/ https://ncbi.nlm.nih.gov/pubmed/31786421 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.radonc.2019.11.015 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|